The utility of ezetimibe therapy in nonalcoholic fatty liver disease
Baek Gyu Jun, Gab Jin Cheon
Korean J Intern Med. 2019;34(2):284-285. Published online 2019 Feb 25 DOI: https://doi.org/10.3904/kjim.2019.043
Citations to this article as recorded by 
Estimation of non-alcoholic steatohepatitis (NASH) disease using clinical information based on the optimal combination of intelligent algorithms for feature selection and classification
Hamed Zamanian, Ahmad Shalbaf
Computer Methods in Biomechanics and Biomedical Engineering.2023; : 1. CrossRef
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Veronika A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi
Biomedicines.2022; 10(2): 274. CrossRef
Study on the Factors Related to Cholesterol Metabolism Pathway and Non-Alcoholic Fatty Liver Disease
越 张
Advances in Clinical Medicine.2022; 12(04): 3703. CrossRef
Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Tieshan Teng, Shuai Qiu, Yiming Zhao, Siyuan Zhao, Dequan Sun, Lingzhu Hou, Yihang Li, Ke Zhou, Xixi Yu, Changyong Yang, Yanzhang Li
International Journal of Molecular Sciences.2022; 23(14): 7841. CrossRef
Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases
Pooja Malhotra, Ravinder K. Gill, Seema Saksena, Waddah A. Alrefai
Frontiers in Medicine.2020;[Epub] CrossRef